kennedys – New frontiers in cell and gene therapies: Comparative regulatory frameworks
The unique and distinctive characteristics of cell and gene therapies (CGTs), also referred to as advanced therapy medicinal products (ATMPs) due to varying terminology from different regulators1, have created alternative regulatory approaches owing to the challenges of regulating them within traditional frameworks.
Read Full Article